Innate Pharma IPHA
NASDAQ IPHA
$2.26 +0.17 (+8.10%)
As of: Aug 21, 2026 · 3:59 PM EDT

Innate Pharma (IPHA) EBITDA Margin Growth (3y) (2022 - 2025)

Innate Pharma (IPHA) EBITDA Margin Growth (3y) (2022 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (3y) (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -377.00
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -204.00
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -537.00
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -1,934.00
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 7,261.00
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 9,003.00
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -11,254.00
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 30,461.00
9 Royalty Pharma 27.27 Bn 26.43 Bn - -2,649.00
10 Innate Pharma 202.03 Mn 202.03 Mn - -187,643.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -187,643.00
Dec 31, 2024 -2,858.00
Dec 31, 2023 -460.00
Dec 31, 2022 3,728.00